Form of Proxy

MINERALYS THERAPEUTICS, INC.

BD Client Code:

Client Name:

Number of Shares Held in a BD Nominee Company:

No.	Proposition		For	Against	Abstain
1	Election of Class II Director for a three-year term to expire at the 2028 Annual Meeting of stockholders: Glenn P. Sblendorio
2	Election of Class II Director for a three-year term to expire at the 2028 Annual Meeting of stockholders: Derek DiRocco, Ph.D.
3	Ratify the appointment of Ernst & Young LLP as Mineralys Therapeutics, Inc.s independent registered public accounting firm for the fiscal year ending December 31, 2025.